Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

Innate Pharma (NasdaqGS:IPHA) Q2 2025 Earnings Call September 17, 2025 08:00 AM ET Company ParticipantsStéphanie Cornen - VP of Investor Relations and CommunicationsSonia Quaratino - CMOYannis Morel - COOFrédéric Lombard - CFOBill Ling - Equity Research AssociateJonathan Dickinson - CEOConference Call ParticipantsSwayampakula Ramakanth - Managing Director and Senior Equity AnalystJustin Zelin - Director and Biotechnology Equity Research AnalystOperatorThank you. I'd now like to turn the call over to Stéphan ...

Innate Pharma (NasdaqGS:IPHA) Q2 2025 Earnings Call September 17, 2025 08:00 AM ET Company ParticipantsStéphanie Cornen - VP - IR, Communications & Commercial StrategyJonathan Dickinson - CEO & DirectorYannis Morel - EVP & COOSonia Quaratino - EVP & Chief Medical OfficerFrédéric Lombard - SVP & CFODaina Graybosch - Senior MD - Immuno-OncologyJustin Zelin - Director - BiotechnologyConference Call ParticipantsSwayampakula Ramakanth - MD & Senior Healthcare AnalystOperatorThank you. I'd now like to turn the ca ...

Innate Pharma (NasdaqGS:IPHA) Q2 2025 Earnings Call September 17, 2025 08:00 AM ET Company ParticipantsStéphanie Cornen - VP of Investor Relations and CommunicationsSonia Quaratino - CMOYannis Morel - COOFrédéric Lombard - CFOBill Ling - Equity Research AssociateJonathan Dickinson - CEOConference Call ParticipantsSwayampakula Ramakanth - Managing Director and Senior Equity AnalystJustin Zelin - Director and Biotechnology Equity Research AnalystOperatorThank you. I'd now like to turn the call over to Stéphan ...

Innate Pharma (NasdaqGS:IPHA) Q2 2025 Earnings Call September 17, 2025 08:00 AM ET Speaker4Thank you. I'd now like to turn the call over to Stéphanie Cornen, Vice President, Investor Relations and Communications. You may begin.Speaker0Good morning and good afternoon, everyone. Thank you for joining us for Innate Pharma H1 2025 Business and Financial Results Conference call. The press release and today's presentation are both available on the investor section of our website. Before we begin, I'd like to remi ...

This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumpti ...

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma Reports First Half 2025 Business Update And Financial Results. ...

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces its participation in the 25th edition of the European Midcap Event. ...

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces conference call and webcast for first half 2025 financial results and business update. ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority "Autorité des Marchés Financiers" ("AMF") on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website. The Company also announced today the filing of its annual report on Form 20-F for the year ending December ...